arrow
Z

Zoe J. Assaf

irccs policlinico gemelli
H指数:22
被引数:4,319

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer

ctDNA指导下的辅助阿特珠单抗治疗在肌肉浸润性膀胱癌中的应用

2025-10-0110
PRE
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial

Entrectinib治疗ROS1-positive晚期非小细胞肺癌: 2/3期BFAST试验

2024-06-192
OAAI
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma

IMvigor010 3期临床试验通过循环肿瘤DNA状态更新总生存期: 辅助阿特珠单抗与肌肉浸润性尿路上皮癌的观察比较

2024-02-0129
PRE
Alectinib for treatment-naive advanced ALK plus NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A
2023-10-010
PRE
Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay
2023-07-314
OAAI
Evaluation of circulating tumor DNA kinetics as a prognostic biomarker for overall survival in metastatic castrate resistant prostate cancer using a novel methylation sequencing research assay
2023-04-040
PRE
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer

基于循环肿瘤DNA的纵向模型与转移性非小细胞肺癌的生存相关

2023-03-1648
OAAI
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
2022-08-0182
OA
Molecular determinants of response to PD-L1 blockade across tumor types
2021-06-2591
OAAI
Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma
2019-07-015
PRE